On December 18, 2025, Werewolf Therapeutics, Inc. (NASDAQ:HOWL) shared a comprehensive pipeline update in which it highlighted clinical progress and 2026 priorities for its INDUKINE programs and ...
Fintel reports that on December 19, 2025, HC Wainwright & Co. maintained coverage of Werewolf Therapeutics (NasdaqGS:HOWL) with a Buy recommendation. Analyst Price Forecast Suggests 819.86% Upside As ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する